Date: Wednesday 19th March 2025
Time: 15:00-16:00 CET | 14:00 - 15:00 GMT
Location: Online via Zoom
Speakers: Dr. Liam Childs, AI working group lead - Paul Ehrlich Institute
Who is this event intended for? Statisticians, Data Scientists, Researchers, Physicians, etc. interested in quantitative decision making.
What is the benefit of attending? Information on AI driven approaches in different applications in research and pharmaceutical development.
This webinar is free to both Members of PSI and Non-Members.
To register for this event, please click here
Artificial Intelligence (AI) is increasingly integrated into the development and regulation of medicinal products, offering new opportunities in drug discovery, clinical trials, and manufacturing. AI-driven approaches, particularly machine learning and bioinformatics, facilitate target identification, optimize patient selection in clinical trials, and enhance process control in pharmaceutical manufacturing. In the context of biomedicine, AI plays a critical role in predicting drug-target interactions, modeling peptide-MHC binding for immunotherapy, and improving the precision of CRISPR-Cas9 genome editing.
Despite its potential, AI applications in medicinal products present challenges, including data quality, algorithm validation, and regulatory compliance. The necessity for robust performance metrics and risk assessment frameworks is paramount to ensure the reliability and safety of AI-driven methodologies.
|
Speaker |
Biography |
Abstract |
|
|
Dr. Liam Childs received his Doctorate in Natural Sciences (Dr. rer. nat.) from the Max-Planck Institute for Molecular Plant Physiology, with a research focus on machine learning and bioinformatics. He has over two decades of experience in artificial intelligence, data science, and bioinformatics and is currently the AI Working Group Lead at the Paul-Ehrlich-Institut in Germany, where he is responsible for developing and implementing the institute's AI strategy. Throughout his career, Liam has held multiple academic and industry positions, including postdoctoral fellowships in bioinformatics at the German Cancer Research Center (DKFZ) and Humboldt University, Berlin, as well as a role as a Senior Software Developer at Gotthardt Healthgroup. |
Artificial Intelligence (AI) is increasingly integrated into the development and regulation of medicinal products, offering new opportunities in drug discovery, clinical trials, and manufacturing. AI-driven approaches, particularly machine learning and bioinformatics, facilitate target identification, optimize patient selection in clinical trials, and enhance process control in pharmaceutical manufacturing. In the context of biomedicine, AI plays a critical role in predicting drug-target interactions, modeling peptide-MHC binding for immunotherapy, and improving the precision of CRISPR-Cas9 genome editing. Despite its potential, AI applications in medicinal products present challenges, including data quality, algorithm validation, and regulatory compliance. The necessity for robust performance metrics and risk assessment frameworks is paramount to ensure the reliability and safety of AI-driven methodologies. |
